Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 0.83 |
| ▸ | KDR | P35968 | 8/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.83 |
| ▸ | GAK | O14976 | 2/20 | 0.83 |
| ▸ | ABL1 | P00519 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CDK1 | P06493 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349430 | 0.93 | EGFR (0.91) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL4232360 | 0.92 | FBP1 (0.84) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL29444884 | 0.91 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL9423 | 0.91 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL30363011 | 0.91 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL5742396 | 0.91 | EGFR (0.86) | FBP1EGFRKDRERBB2GAK | |
| SCHEMBL28641557 | 0.91 | FBP1 (0.83) | FBP1EGFRKDRERBB2GAK | |
| Hydrochloric Acid SCHEMBL29369196 | 0.90 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK | |
| Hydrochloric Acid SCHEMBL30362813 | 0.90 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK | |
| Hydrochloric Acid SCHEMBL93918 | 0.90 | EGFR (1.00) | FBP1EGFRKDRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3700901-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | FBP1 3252/4885EGFR 2005/4885KDR 327/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | FBP1 3252/4885EGFR 2005/4885KDR 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.